Cetuximab (EGFR inhibitor)
Sponsors
Jacobio Pharmaceuticals Co., Ltd., Gruppo Oncologico del Nord-Ovest, Vanderbilt-Ingram Cancer Center, Sun Yat-sen University, Washington University School of Medicine
Conditions
Advanced Cutaneous Squamous Cell CarcinomaAdvanced Solid TumorCRCColorectal CancerCutaneous Squamous Cell Carcinoma (CSCC)Head and Neck Squamous Cell CarcinomaKidney TransplantKidney Transplant Recipient
Phase 1
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
CompletedNCT05002270
Start: 2021-09-03End: 2025-02-12Updated: 2026-01-13
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
RecruitingNCT07217028
Start: 2026-04-24End: 2030-09-01Target: 25Updated: 2026-05-11
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer
RecruitingNCT07790510
Start: 2026-08-12End: 2030-09-30Target: 180Updated: 2026-08-27
Phase 2
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Not yet recruitingNCT07621497
Start: 2026-06-01End: 2030-06-01Target: 229Updated: 2026-06-02
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Not yet recruitingNCT07715734
Start: 2026-09-30End: 2031-03-31Target: 22Updated: 2026-07-20